▎藥明康德/報道

▲Lasmiditan分子結(jié)構(gòu)式（圖片來源：Anypodetos [Public domain]）

▲Reyvow在3期臨床試驗中的部分療效結(jié)果（圖片來源：參考資料[3]）

參考資料：

[1] FDA approves new treatment for patients with migraine. Retrieved October 11, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-patients-with-migraine-300937273.html

[2] Lilly's REYVOW? (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval. Retrieved October 11, 2019, from https://www.prnewswire.com/news-releases/lillys-reyvow-lasmiditan-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-receives-fda-approval-300937322.html

版權(quán)說明：本文來自藥明康德內(nèi)容團隊沐祷，歡迎個人轉(zhuǎn)發(fā)至朋友圈嚷闭，謝絕媒體或機構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”赖临，獲取轉(zhuǎn)載須知胞锰。